491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Category Primary study
JournalAnnals of Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 3d6e81d491e250e91135d57aa7924ed6b7b798dc
First added on: Feb 15, 2025